why choose us

Course: Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations

CME Credits: 1.00

Released: 2022-03-02

Although the Ad26.COV2.S vaccine (Janssen) showed an efficacy of 85.4% against severe and critical COVID-19 in the pivotal trial, its effectiveness in the general population against COVID-19 hospitalization was estimated to be approximately 68%,, compared with approximately 90% for mRNA vaccines. However, to date, the effectiveness of Ad26.COV2.S has not been compared with that of other COVID-19 vaccines. In France, the Ad26.COV2.S vaccine was used from April 24, 2021, in people aged 55 years or older, whereas the BNT162b2 mRNA vaccine (Pfizer-BioNTech) was the most widely administered (78% of first doses). As of the end of July 2021, 19 million people aged 55 years or older (84% of the population in that age group) were partially or fully vaccinated. In this comparative effectiveness research study, we compare the effectiveness of full vaccination with Ad26.COV2.S vs BNT162b2 against COVID-19–related hospitalization.


Educational Objective
To identify the key insights or developments described in this article


View Full Course